Cantor Fitzgerald set a $10.00 price target on Teva Pharmaceutical Industries (NYSE:TEVA) in a research note issued to investors on Thursday. The brokerage currently has a hold rating on the stock.

“This morning Teva announced more details of its new strategic plan under CEO Kare Schultz, including the layoff of 14,000 people. This is meaningfully above the Street’s estimate of 10,000 jobs.”,” Cantor Fitzgerald’s analyst wrote.

Other analysts have also issued research reports about the company. BTIG Research raised Teva Pharmaceutical Industries from a neutral rating to a buy rating and set a $24.00 target price on the stock in a report on Monday, September 11th. Gabelli reissued a buy rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, September 13th. ValuEngine raised Teva Pharmaceutical Industries from a hold rating to a buy rating in a research note on Monday, October 2nd. Evercore ISI set a $38.00 price objective on Teva Pharmaceutical Industries and gave the company a buy rating in a research note on Wednesday, October 25th. Finally, TheStreet lowered Teva Pharmaceutical Industries from a c- rating to a d+ rating in a research note on Friday, August 25th. Five equities research analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries currently has an average rating of Hold and a consensus target price of $20.65.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at $18.61 on Thursday. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. The firm has a market capitalization of $18,907.76, a price-to-earnings ratio of 4.30 and a beta of 0.55. Teva Pharmaceutical Industries has a twelve month low of $10.85 and a twelve month high of $38.31.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were given a dividend of $0.085 per share. The ex-dividend date was Monday, November 27th. This represents a $0.34 annualized dividend and a yield of 1.83%. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is presently -12.10%.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Security National Bank of Sioux City Iowa IA lifted its position in Teva Pharmaceutical Industries by 0.4% during the second quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock worth $724,000 after buying an additional 87 shares during the period. Bronfman E.L. Rothschild L.P. lifted its position in Teva Pharmaceutical Industries by 2.6% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after buying an additional 94 shares during the period. Sheaff Brock Investment Advisors LLC lifted its position in Teva Pharmaceutical Industries by 3.6% during the second quarter. Sheaff Brock Investment Advisors LLC now owns 8,389 shares of the company’s stock worth $279,000 after buying an additional 294 shares during the period. Bank of Nova Scotia lifted its position in Teva Pharmaceutical Industries by 8.3% during the second quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after buying an additional 528 shares during the period. Finally, First National Trust Co. lifted its position in Teva Pharmaceutical Industries by 6.7% during the second quarter. First National Trust Co. now owns 8,878 shares of the company’s stock worth $295,000 after buying an additional 555 shares during the period. Hedge funds and other institutional investors own 52.05% of the company’s stock.

WARNING: This report was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/cantor-fitzgerald-analysts-give-teva-pharmaceutical-industries-teva-a-10-00-price-target/1769642.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.